MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-19-2026
Tandem Diabetes Care Net Income 2011-2026 | TNDM
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Tandem Diabetes Care
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -589 K | 755 K | -223 M | -94.6 M | 15.6 M | -34.4 M | -24.8 M | -123 M | -73 M | -83.4 M | -72.4 M | -79.5 M | -63.1 M | -33 M | -25.5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 15.6 M | -223 M | -60.9 M |
Quarterly Net Income Tandem Diabetes Care
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -21.2 M | -52.4 M | -131 M | - | -23.3 M | -30.8 M | -42.7 M | - | -33 M | -35.8 M | -124 M | - | -49 M | -15.1 M | -14.7 M | 10.8 M | 5.79 M | 4.01 M | -5.04 M | 17 M | -9.41 M | -27.1 M | -14.9 M | 2.65 M | -2.9 M | -1.51 M | -23 M | 3.69 M | -34.2 M | -59.4 M | -32.7 M | -11.4 M | -16 M | -21.8 M | -23.8 M | -14.8 M | -29.8 M | -18.3 M | -20.5 M | -12.1 M | -19.6 M | -19.5 M | -21.2 M | -18.5 M | -19.9 M | -19.2 M | -22 M | -23.6 M | -13.1 M | -15.3 M | -11.2 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 17 M | -131 M | -23.1 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BIOLASE
BIOL
|
-20.6 M | - | -13.19 % | $ 166 K |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
-18.6 M | - | - | $ 1.77 B | USA |
 |
AdaptHealth Corp.
AHCO
|
-70.8 M | $ 13.38 | 2.29 % | $ 1.81 B | USA |
 |
Allied Healthcare Products
AHPI
|
-1.94 M | - | 3.58 % | $ 2.21 M | USA |
 |
BioSig Technologies
BSGM
|
-463 M | - | 37.08 % | $ 85.7 M | USA |
 |
Avinger
AVGR
|
-18.3 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-59.7 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
53.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-12.3 M | - | -5.86 % | $ 30.6 M | USA |
 |
Cardiovascular Systems
CSII
|
-36.9 M | - | 0.15 % | $ 844 M | USA |
 |
Electromed
ELMD
|
7.54 M | $ 25.74 | -1.0 % | $ 218 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-19 M | $ 3.28 | 1.86 % | $ 123 M |  France |
 |
Conformis
CFMS
|
-50.5 M | - | - | $ 16.4 M | USA |
 |
Globus Medical
GMED
|
538 M | $ 90.74 | -3.16 % | $ 12.3 B | USA |
 |
Dynatronics Corporation
DYNT
|
-10.9 M | - | 14.99 % | $ 929 K | USA |
 |
Cytosorbents Corporation
CTSO
|
-8.2 M | $ 0.6 | -1.96 % | $ 37.3 M | USA |
 |
Apollo Endosurgery
APEN
|
-39.8 M | - | - | $ 475 M | USA |
 |
ClearPoint Neuro
CLPT
|
-25.5 M | $ 11.08 | -1.16 % | $ 314 M | USA |
 |
Helius Medical Technologies
HSDT
|
-8.85 M | $ 2.08 | -1.89 % | $ 1.26 M | USA |
 |
Eargo
EAR
|
-157 M | - | - | $ 10.2 M | USA |
 |
CryoLife, Inc.
CRY
|
-16.7 M | - | -4.14 % | $ 702 M | USA |
 |
Second Sight Medical Products
EYES
|
-26.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
LENSAR
LNSR
|
-34.3 M | $ 5.35 | 2.69 % | $ 64 M | USA |
 |
Soliton, Inc.
SOLY
|
-14.5 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.14 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-10.9 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
LivaNova PLC
LIVN
|
-242 M | $ 61.29 | -3.34 % | $ 3.34 B |  Britain |
 |
Misonix, Inc.
MSON
|
-17.4 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-24.9 M | - | - | $ 111 M |  Canada |
 |
Orthofix Medical
OFIX
|
-92.2 M | $ 11.91 | -3.33 % | $ 472 M |  Curacao |
 |
PAVmed
PAVM
|
401 K | $ 8.94 | 6.43 % | $ 5.99 M | USA |
 |
Pulmonx Corporation
LUNG
|
-54 M | $ 1.23 | -4.3 % | $ 50 M | USA |
 |
Butterfly Network
BFLY
|
-72.5 M | $ 5.16 | -5.84 % | $ 1.09 B | USA |
 |
Intersect ENT, Inc.
XENT
|
-72.3 M | - | - | $ 955 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-39.6 M | $ 15.14 | -4.3 % | $ 355 M | USA |
 |
Delcath Systems
DCTH
|
2.7 M | $ 10.55 | -2.68 % | $ 378 M | USA |
 |
IRIDEX Corporation
IRIX
|
-4.44 M | $ 1.04 | -3.7 % | $ 17.6 M | USA |
 |
Sintx Technologies
SINT
|
-10.4 M | $ 2.15 | -8.51 % | $ 5.96 M | USA |
 |
CONMED Corporation
CNMD
|
47.1 M | $ 36.79 | -2.85 % | $ 1.14 B | USA |
 |
Inspire Medical Systems
INSP
|
145 M | $ 55.11 | 0.07 % | $ 1.62 B | USA |
 |
Integer Holdings Corporation
ITGR
|
103 M | $ 84.64 | -0.83 % | $ 2.94 B | USA |
 |
Invacare Corporation
IVC
|
-20.6 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.07 B | $ 82.28 | -1.41 % | $ 48.1 B | USA |
 |
Stryker Corporation
SYK
|
849 M | $ 321.43 | -2.3 % | $ 123 B | USA |
 |
Tactile Systems Technology
TCMD
|
19.1 M | $ 23.57 | -2.76 % | $ 539 M | USA |
 |
TELA Bio
TELA
|
-38.8 M | $ 0.78 | -2.46 % | $ 36.6 M | USA |
 |
MiMedx Group
MDXG
|
48.6 M | $ 3.4 | 1.8 % | $ 502 M | USA |